Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ECG could reveal hidden heart recovery after ablation

NCT ID NCT07708818

Knowledge-focused Sponsor: Ewha Womans University Mokdong Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests whether an artificial intelligence analysis of standard electrocardiograms (ECGs) can track heart muscle recovery in people with atrial fibrillation and mild heart failure who undergo catheter ablation. Researchers will follow 1,000 participants for a year, using AI to calculate a heart failure risk score from each ECG and comparing it with traditional measures like echocardiograms and blood tests. The goal is to see if this digital tool can serve as a simple, noninvasive way to monitor how well the heart heals after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation
What this could lead to
If successful, this could show that AI-ECG is a reliable way to monitor heart recovery after ablation, potentially guiding personalized treatment decisions.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly prove that AI-ECG improves outcomes. Results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults with symptomatic paroxysmal or persistent atrial fibrillation and heart failure with mildly reduced ejection fraction (left ventricular ejection fraction 41-49%) who are scheduled to undergo first-time catheter ablation. Participants are prospectively enrolled at five tertiary referral centers and are additionally required to have at least one feature suggestive of latent heart failure substrate, including elevated natriuretic peptide levels, impaired global longitudinal strain, increased left atrial volume index, elevated E/e' ratio, or exertional intolerance. All participants undergo standardized longitudinal follow-up with serial 12-lead electrocardiography, echocardiography, biomarker assessment, and clinical evaluation for 12 months after catheter ablation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Symptomatic paroxysmal or persistent atrial fibrillation * Scheduled for first-time catheter ablation * Left ventricular ejection fraction between 41% and 49% measured by transthoracic echocardiography within 3 months before ablation * At least one analyzable sinus rhythm 12-lead electrocardiogram before ablation * At least one latent heart failure substrate feature: * Elevated NT-proBNP * Increased left atrial volume index (\>34 mL/m²) * Average E/e' ≥14 * Reduced global longitudinal strain * Mild pulmonary hypertension * Exertional intolerance suggestive of early heart failure * Ability to provide written informed consent Exclusion Criteria: * Left ventricular ejection fraction ≤40% * Previous atrial fibrillation catheter ablation * Significant valvular heart disease requiring intervention * Hypertrophic or infiltrative cardiomyopathy * Acute coronary syndrome, coronary revascularization, or myocarditis within 3 months * Severe renal dysfunction requiring dialysis * Active malignancy with life expectancy \<1 year * Inadequate electrocardiographic or echocardiographic image quality * Pregnancy * Inability or unwillingness to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Heart failure with mildly reduced ejection fraction (hfmref)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ewha Womans University Mokdong Hospital

    Seoul, 07804, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.